Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Angiodynamics Inc (NQ: ANGO )

7.510 +0.090 (+1.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 306,625
Open 7.470
Bid (Size) 7.510 (8)
Ask (Size) 7.520 (18)
Prev. Close 7.420
Today's Range 7.390 - 7.625
52wk Range 5.260 - 8.250
Shares Outstanding 38,444,076
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AngioDynamics Announces CE Mark Approval in Europe for the Auryon System
From AngioDynamics, Inc.
Via Business Wire
PDD Holdings, Daqo New Energy And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga

Performance

YTD
-6.48%
-6.48%
1 Month
+0.94%
+0.94%
3 Month
+22.31%
+22.31%
6 Month
+35.07%
+35.07%
1 Year
+5.18%
+5.18%

More News

Read More
AngioDynamics to Participate in Upcoming Investor Conferences
From AngioDynamics, Inc.
Via Business Wire
Nasdaq Edges Lower; Morgan Stanley Earnings Top Views
Via Benzinga
Medical Devices Maker AngioDynamics Lays Out Growth Plans, Issues Upbeat Annual Guidance
Via Benzinga
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Crude Oil Down 1%; Bank of America Posts Upbeat Earnings
Via Benzinga
Exposures Fossil Fuels
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
ANGO Stock Earnings: AngioDynamics Beats EPS, Beats Revenue for Q4 2024
Via InvestorPlace
AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Report Fiscal 2024 Fourth Quarter and Full-Year Financial Results on July 16, 2024
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions
From AngioDynamics, Inc.
Via Business Wire
Insiders Buying Zumiez And 3 Other Stocks
Via Benzinga
Medical Devices Focused AngioDynamics Unveils Upbeat 2024 Financial Outlook, Stock Soars
Via Benzinga
Exposures Product Safety
ANGO Stock Earnings: AngioDynamics Misses EPS, Misses Revenue for Q3 2024
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE
From AngioDynamics, Inc.
Via Business Wire
Earnings Scheduled For April 4, 2024
Via Benzinga
AngioDynamics Resolves Decade-Long Patent Litigation With Becton, Dickinson In Settlement Agreement
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference
From AngioDynamics, Inc.
Via Business Wire
Hidden Gems: 7 Oversold Stocks Ready for a Major Rebound
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.